Page 16 - ebook

고형암 항암치료 환자의 부작용 관리 Nausea and Vomiting

Classification Agent

Parenteral Moderate emetic risk Carboplatin AUC <4
Carmustine ≤ 250 mg/m 2
Clofarabine
Cyclophosphamide ≤ 1500 mg/m 2
Cytarabine >200 mg/m 2
Dactinomycin
Daunorubicin
Cytarabine and Daunorubicin combination
Dinutuximab
Doxorubicin < 60 mg/m 2
Epirubicin ≤90 mg/m 2
Fam-trastuzumab deruxtecan-nxki
Idarubicine
Ifosfamide <2 g/m per dose
2
Irinotecan
Lubinectedin
Melphalan < 140 mg/m 2
Methotrexate ≥ 250 mg/m 2
Oxaliplatin
Temozolomide
Trabectedin

Low emetic risk Ado-transtuzumab emtansine
Aldesleukin ≤ 12 million IU/m 2
Amifostine ≤ 300 mg/m 2
Arsenic trioxide
Axicabtagene ciloleucel
Belinostat
Brexucabtagene autoleucel
Brentuximab vedotin
Cabazitaxel
Carfilzomib
Copanlisib
Cytarabine 100-200 mg/m 2
Docetaxel
Doxorubicin (liposomal)
Enfortumab vedotin-ejfv
Eribulin
Etoposide
5-FU
Floxuridine
Gemcitabine
Gemtuzumab ozogamicin
Onotuzumab ozogamicin
Isatuximab-irfc
Ixabepoline
Methtrexate 50-250 mg/m 2

16